New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;NVS;CBST;TEVA;JAZZ;BP;CHK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 22, 2014
11:09 EDTNVSFTC puts conditions on Lilly's proposed acquisition of Novartis Animal Health
Global pharmaceutical company Eli Lilly and Company (LLY) has agreed to divest its Sentinel product line of medications for treating heartworm disease in dogs in order to settle FTC charges that its proposed $5.4B acquisition of Novartis (NVS) Animal Health would likely be anticompetitive. Under the proposed settlement, Eli Lilly will divest its Sentinel product line and associated assets to the French pharmaceutical company, Virbac. Indianapolis-based Eli Lilly, through its Elanco Animal Health division, and Switzerland-based Novartis AG’s Novartis Animal Health business unit both develop and market a wide range of animal health products, including medications to treat diseases and conditions affecting pets and livestock. Reference Link
11:00 EDTCBSTOptions with decreasing implied volatility
Subscribe for More Information
09:21 EDTGSKLigand partner Glaxo files sNDA seeking additional indication for Promacta
Subscribe for More Information
08:42 EDTBPBP cites remediation, lower oil prices as rationale for lower penalty, FT says
Subscribe for More Information
December 21, 2014
19:45 EDTBPSaudis say oil prices will recover as global economies grow,The Independent says
Subscribe for More Information
16:42 EDTBPSaudis say no cut in oil production is forthcoming, Reuters says
Signalling that it will ride out the recent volatility in oil markets, Saudi Arabia said it will not cut oil production even if non-OPEC nations did so, Reuters reports. "If they want to cut production they are welcome: We are not going to cut, certainly Saudi Arabia is not going to cut," commented Saudi Oil Minister Ali al-Naimi. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
14:16 EDTBPU.S seeks up to $18B in water-pollution fines from BP for spill, Bloomberg says
Subscribe for More Information
12:21 EDTJAZZJazz Pharmaceuticals gets FDA okay for intravenous administration of Erwinaze
Subscribe for More Information
December 19, 2014
18:09 EDTCBSTCubist confirms FDA approval of new antibiotic ZERBAXA
Cubist Pharmaceuticals announced the U.S. FDA approved ZERBAXA for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections caused by designated susceptible Gram-negative bacteria. The approval of ZERBAXA was supported by positive data from two pivotal Phase 3 clinical trials—one in patients with cUTI and the other in patients with cIAI. Both trials met the pre-specified primary endpoints agreed upon with the FDA and European Medicines Agency.
18:02 EDTCBSTFDA approves new antibacterial drug Zerbaxa
Subscribe for More Information
10:19 EDTCBSTOptions with decreasing implied volatility
Subscribe for More Information
08:08 EDTTEVATeva Announces FDA Approval of QNASL for young children
Subscribe for More Information
08:07 EDTCBSTMerck begins tender offer to acquire Cubist
Subscribe for More Information
December 18, 2014
12:55 EDTTEVACourt delays Teva's launch of generic Celebrex, Globes reports
Subscribe for More Information
12:46 EDTTEVATeva in legal dispute with former Russian partner, Globes reports
Subscribe for More Information
10:58 EDTCBSTTetraphase seen as takeover target after antibiotic trial success
Subscribe for More Information
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
08:09 EDTCBSTAlnylam names Cubist CEO Michael Bonney to board of directors
Subscribe for More Information
07:47 EDTBPJacobs Engineering selected by BP as strategic supplier
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 17, 2014
15:09 EDTNVSNovartis unit gets FDA approval for swimmer’s ear treatment
Subscribe for More Information
13:32 EDTTEVAPerrigo jumps after analyst discusses potential takeover by Teva
Subscribe for More Information
10:36 EDTCBSTCowen pharmaceuticals analysts hold an analyst/industry conference call
Analyst Research Team discusses the imminent Merck/Cubist Zerbaxa opportunity and the Cempra SOLITAIRE-ORAL Trial readout on an Analyst/Industry conference call to be held on December 17 at 2 pm.
10:02 EDTCBSTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:26 EDTTEVAPerrigo would be good acquisition for Teva, says RBC Capital
RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.
07:29 EDTNVSFDA PDUFA Date for Novartis Bexsero is December 17, 2014
Subscribe for More Information
06:29 EDTCBSTCubist downgraded to Neutral from Buy at UBS
Subscribe for More Information
06:08 EDTCBSTStocks with implied volatility below IV index mean; NUGT CBST
Subscribe for More Information
December 16, 2014
09:52 EDTTEVAFDA ruling on generic Celebrex reversed by appeals court
Subscribe for More Information
08:47 EDTNVSHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
07:06 EDTNVSBioLineRx and Novartis enter into strategic collaboration agreement
Subscribe for More Information
06:02 EDTCBSTStocks with implied volatility below IV index mean; QCOM CBST
Subscribe for More Information
05:48 EDTNVSNovartis gains FDA approval for Signifor LAR
Subscribe for More Information
December 15, 2014
13:00 EDTBPEU conditionally approves BP acquisition of jet fuel unit, Reuters says
Subscribe for More Information
10:36 EDTCBSTOptions with increasing implied volatility
Subscribe for More Information
December 14, 2014
17:07 EDTBPOPEC's Badri says group will withstand oil price fall, Reuters says
Subscribe for More Information
December 12, 2014
16:33 EDTCBSTStocks finish week lower amid steep decline in oil prices
Subscribe for More Information
10:01 EDTTEVAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:49 EDTTEVATeva upgraded at Sterne Agee
Subscribe for More Information
08:36 EDTNVSNovartis reports BOLERO-1 trial did not meet primary objective
Subscribe for More Information
07:06 EDTTEVATeva upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
06:51 EDTBPBrent crude oil fell to five year low, Reuters reports
Subscribe for More Information
06:12 EDTCBSTStocks with implied volatility below IV index mean; AEO CBST
Subscribe for More Information
05:31 EDTNVSNovartis reports Cosentyx 'superior' in head-to-head psoriasis study
Subscribe for More Information
December 11, 2014
16:16 EDTJAZZJazz Pharmaceuticals initiates rolling NDA submission for defibrotide
Subscribe for More Information
09:39 EDTTEVATeva FY15 outlook appears strong, reasonable, says BMO Capital
Subscribe for More Information
07:24 EDTTEVATeva to host conference call
Subscribe for More Information
07:12 EDTTEVATeva sees FY15 Copaxone sales $3.5B-$3.7B
Sees FY15 Treanda sales $670M-$750M. Sees FY15 ProAir family sales $470M-$580M, Azilect sales $350M-$400M and Nuvigil sales $300M-$330M. Erez Vigodman, President & CEO of Teva, said, "Generics remain at the heart of our business, both as the cornerstone of the Company, but also as an area that has great impact on society. At the same time, we anticipate four specialty product approvals and five submissions in 2015 – which we believe will improve treatment options for patients, and add value for all of our stakeholders." The company expects 2015 generic revenues in the United States to be $4.2B-$4.6B, $2.6B-$3.0B in Europe and $2.0B-$2.3B in its ROW markets. Results of its specialty segment are expected to be impacted by the introduction of two AB-rated generic competitors to Copaxone in the U.S. beginning in September 2015, which is a modeling assumption only, as well as by increased competition from oral products for the treatment of multiple sclerosis. In addition, the company is expecting to invest in a significant number of product launches and in its specialty pipeline. "All of these will result in lower profit and profitability, as we focus on generating growth over the next few years," Teva said.
07:08 EDTTEVATeva sees FY15 gross profit 59.5%-61.5%
Teva sees FY15 cash flow from operations $4.3B-$4.7B and free cash flow $3.5B-$3.7B.
07:07 EDTTEVATeva sees spending $1B-$1.2B on share buybacks in 2015
Subscribe for More Information
07:02 EDTTEVATeva sees FY15 EPS $5.00-$5.30, consensus $5.06
Sees FY15 revenue $19B-$19.4B, consensus $20.07B.
05:53 EDTCBSTStocks with implied volatility below IV index mean; PCLN CBST
Subscribe for More Information
December 10, 2014
16:44 EDTCHKOn The Fly: Closing Wrap
Subscribe for More Information
12:42 EDTBPBP volatility increases as shares trade at 30-month low
BP December and January call option implied volatility is at 31; compared to its 26-week average of 17 according to Track Data, suggesting large price movement.
10:00 EDTBPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:31 EDTTEVATeva announces launch of first generic Celebrex capsules in the U.S.
Teva Pharmaceutical Industries (TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex Capsules in the United States. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib Capsules. Celebrex Capsules, marketed by Pfizer (PFE) had annual sales of approximately $2.56B in the United States, according to IMS data as of October 2014.
06:06 EDTBPBP sees $1B in group-wide restructuring charges over coming year
"Although the current environment is challenging, BP is well-positioned to respond and manage our Upstream business for the long term,” said Upstream CEO Lamar McKay. “We expect to see growth from our conventional and deepwater assets and an increasing contribution from gas. And we also have a quality pipeline of opportunities that we believe are capable of extending underlying growth well beyond 2020. Our focus throughout will remain firmly on safe operations, execution efficiency and greater plant reliability.” BP also said that, as part of its wider ongoing Group-wide programme to simplify across its Upstream and Downstream activities and corporate functions, it expects to incur non-operating restructuring charges of circa $1B in total over the next five quarters, including the current quarter. Details of these charges and further guidance on the program are expected to be given with each quarter’s results. Across the Group, BP has said it will be looking to pare or re-phase capital expenditure without compromising safety or future growth. In October, BP told investors this could result in reductions of $1B-$2B in capital expenditure across the Group in 2015 against guidance of $24B-$26B laid out in March. This will be reviewed further as part of the 2015 plan, recognising the current outlook for oil prices. Between now and 2020, the Upstream team’s focus will be on delivery, through safe and reliable operations, strong execution in the existing base business, and the start-up of a suite of new projects which are expected to be capable of adding over 900,000 barrels of oil equivalent a day of net incremental production to BP’s portfolio by 2020. BP will also be progressing opportunities expected to continue to drive underlying growth into the next decade as it builds out its well-established conventional and deepwater oil positions and a distinctive and material portfolio of gas options.
06:01 EDTCBSTStocks with implied volatility below IV index mean; PCLN CBST
Subscribe for More Information
05:53 EDTBPBP upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded BP (BP) to Buy saying shares could see an inflection point in 2015 with the Macondo penalty phase going to trial in January. Deutsche coupled the upgrade of BP with a downgrade of Royal Dutch Shell (RDS.A) to Hold.
05:51 EDTCBSTStocks with implied volatility movement; CBST T
Subscribe for More Information
December 9, 2014
16:28 EDTCBSTOn The Fly: Closing Wrap
Stocks on Wall Street opened in the red on the heels of a sharp sell-off in China and amid continued concern over tumbling oil prices. The domestic economic calendar offered little in the way of a catalyst and the market moved in a narrow range throughout the morning. However, the averages began to pare their losses once the European markets closed. By mid-afternoon the averages had turned mixed with the Nasdaq higher, the S&P flat, and the Dow the laggard, which is the way the trading day closed. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' optimism index rose to 98.1 from a prior reading of 96.1. The JOLTS report showed job openings increased 149K to 4.83M in October, which was above the expectation for 4.795M openings. Wholesale sales increased 0.2% in October and inventories grew 0.4%, both of which were better than expected. In Asia, China's Shanghai composite index plunged 5.4%, making for the stock market's sharpest selloff in years, after the country’s securities clearing house raised the threshold for the type of collateral used for short-term loans and policymakers warned about potentially slower economic growth. In Europe, Greek stocks and bonds also tumbled after a move to bring forward presidential elections, which could potentially derail Greece’s bailout and austerity efforts. COMPANY NEWS: Verizon (VZ) was among the Dow's worst performers, sinking $1.98, or 4.05%, to $46.92 after the company warned that Q4 impacts of its promotional offers, together with the strong customer volumes this quarter, will put short-term pressure on its earnings per share. After last night's commentary from the company, Robert W. Baird downgraded Verizon shares to Neutral from Outperform and lowered its price target on the stock to $50 from $54... Merck (MRK) also weighed on the Dow, as the drugmaker fell $1.87, or 3.02%, to $60.01 after a Delaware court denied Cubist's (CBST) bid to stop Hospira (HSP) from selling a generic version of Cubicin in 2016. Merck announced just yesterday morning that it had agreed to buy Cubist in a transaction with a total value of approximately $9.5B. The news is a "tough start" to Merck's takeover and makes the $9.5B buyout price look $2B to $3B too high, according to analysts at Leerink. Shares of Cubist also fell $xxx, or xxx%, to $xxx following the court ruling. MAJOR MOVERS: Among the notable gainers was bluebird bio (BLUE), which surged $35.39, or 72.39%, to $84.28 after the company announced data from eight subjects treated with its LentiGlobin drug product and Piper Jaffray more than doubled its price target for the shares to $112 from $52. Among the noteworthy losers was Conn's (CONN), which plunged $14.26, or 40.64%, to $20.83 after unexpectedly reporting losses for its third fiscal quarter, withdrawing its FY15 guidance and announcing the departure of its CFO. Also lower was Spirit Airlines (SAVE), which slid $10.70, or 12.67%, to $73.77 after the company said last night that since late October there has been compression in the fare structure for close-in bookings, believed to be driven by the industry’s willingness to trade lower fuel prices for lower fares. Also, this morning, Raymond James downgraded Spirit Airlines to Market Perform from Outperform, citing valuation, European deflation headwinds, and earnings that are still being revised down. INDEXES: The Dow fell 51.28, or 0.29%, to 17,801.20, the Nasdaq rose 25.77, or 0.54%, to 4,766.46, and the S&P 500 slipped 0.49, or 0.02%, to 2,059.82.
13:49 EDTCBSTCubist downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Cubist (CBST) after the company agreed to be acquired by Merck (MRK).
13:08 EDTCBSTMerck may have paid $2B-$3B too much for Cubist, analyst says
Subscribe for More Information
12:25 EDTCBSTOn The Fly: Midday Wrap
Subscribe for More Information
11:40 EDTBPBP to invest $12B in Egypt over next five years, Reuters reports
Subscribe for More Information
10:23 EDTCBST, GSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:19 EDTCBSTHigh option volume stocks
Subscribe for More Information
10:08 EDTCBSTHigh option volume stocks
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
08:39 EDTBPBP to close U.S. cellulosic operations, Bloomberg reports
Subscribe for More Information
08:31 EDTJAZZJazz, Concert say Phase 1 JZP-386 evaluation not done at highest dosage
Subscribe for More Information
08:23 EDTCBSTMerck has 'no way out' of Cubist deal after court decision, says Leerink
Subscribe for More Information
08:12 EDTCBSTMerck still sees Cubist acquisition neutral to modestly accretive to 2015 EPS
Merck (MRK) issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. The company continues to believe the acquisition of Cubist (CBST) will create strong fundamental value for Merck’s shareholders. The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1B of revenue to its 2015 base, with strong growth potential thereafter. The court’s decision does not change Merck’s expectation that the transaction will be neutral to modestly accretive to 2015 non-GAAP EPS. The company also continues to expect that the transaction will contribute mid-single digit accretion on a percentage basis to non-GAAP EPS in 2016, and will continue to be accretive thereafter.
08:11 EDTCBSTCubist downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
07:44 EDTGSK, TEVAAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:20 EDTCBSTCubist downgraded to Neutral from Buy at Mizuho
Subscribe for More Information
05:48 EDTCBSTCubist downgraded to Hold from Buy at Jefferies
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
19:00 EDTCBSTCubist CEO says Cubicin patent ruling will not affect Merck transaction
Subscribe for More Information
18:24 EDTCBSTOn The Fly: After Hours Movers
Subscribe for More Information
18:00 EDTCBSTCubist loses bid to stop Hospira's generic Cubicin after 2016, Bloomberg says
Cubist's (CBST) patent for Cubicin that expires in June 2016 upheld by judge, Bloomberg added. Note that this morning Merck (MRK) and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash.
17:54 EDTCBSTFour Cubist Cubicin patents invalidated as Hospira wins ruling, Bloomberg says
Subscribe for More Information
17:30 EDTCBSTMerck acquisition of Cubist could be a 'winner', Barron's says
Subscribe for More Information
17:30 EDTCBSTMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
17:03 EDTCBSTJudge may have found in favor of Hospira in Cubist case,CNBC's Meg Tirrell says
CNBC's Meg Tirrell said in a tweet: "Whoa. $CBST Hospira decision out -- "appears judge may have found in favor of Hospira on several points," ISI's @MarkSchoenebaum says." Reference Link
16:24 EDTCBSTOn The Fly: Closing Wrap
Stocks on Wall Street were lower amid another drop in crude oil prices, which tumbled to five-year lows. The market opened slightly lower following weaker than expected data from China and Japan, with nothing of note on the domestic calendar to get buyers involved in the day’s activity. Near noon, the averages gained downside momentum and though the market pared its losses several times, it was never able to gain any steam to pull the indexes back into the green. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Asia, Chinese exports rose 4.7% from a year earlier in November, which missed the consensus estimate for an 8% increase. Chinese imports fell 6.7% from the prior year last month, compared with projections for a 3.8% increase. Additionally, Japan's revised third quarter gross domestic product estimate showed the economy shrank more than initially thought, with growth contracting an annualized 1.9%. COMPANY NEWS: Shares of Cubist Pharmaceuticals (CBST) surged $26.24, or 35.29%, to $100.60 after Merck (MRK) agreed to acquire the maker of next-generation antibiotics for $102 per share in cash, or $8.4B and the assumption of $1.1B in debt. A number of other antibiotic makers also climbed, including Tetraphase (TTPH), which rose $2.45, or 8.82%, to $30.24, and Cempra (CEMP), which advanced $1.64, or 11.37%, to $16.06, while shares of Merck finished fractionally higher, adding 39c, or 0.63%, to $61.88 following the deal announcement. MAJOR MOVERS: Among the notable gainers following their presentations at the American Society of Hematology, or ASH, annual meeting were Calithera Biosciences (CALA), which gained $2.38, or 22.52%, to $12.95, and Acceleron Pharma (XLRN), which jumped $5.11, or 13.6%, to $42.67. Among the noteworthy losers was McDonald's (MCD), which fell $3.70, or 3.84%, to $92.61 after the Dow member reported a 2.2% decline in global same-restaurant sales in November. Additionally, the fast-food giant warned that its fourth quarter results would be hurt by its sales pressures, supplier issues in China and a stronger U.S. dollar. Also lower were shares of Liquidity Services (LQDT), which plunged $2.77, or 27.0%, to $7.49 after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with surplus merchandise. INDEXES: The Dow fell 106.31, or 0.59%, to 17,852.48, the Nasdaq dropped 40.06, or 0.84%, to 4,740.69, and the S&P 500 slipped 15.06, or 0.73%, to 2,060.31.
14:28 EDTCBSTCubist downgraded to Neutral from Buy at SunTrust
Subscribe for More Information
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information
13:12 EDTCBSTMerck paid full price but made good deal for Cubist, says UBS
Subscribe for More Information
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
12:40 EDTCBSTOn The Fly: Midday Wrap
Subscribe for More Information
12:25 EDTCBSTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTNVS, TEVALeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:53 EDTBPBP to continue advocating for probe of suspicious, implausible spill claims
Subscribe for More Information
10:11 EDTCBSTHigh option volume stocks
Subscribe for More Information
10:11 EDTBPBP's plea to review Deepwater Horizon settlement rejected, WSJ reports
Subscribe for More Information
09:20 EDTCBSTOn The Fly: Pre-market Movers
Subscribe for More Information
08:30 EDTCBSTMerck says deals with Cubist includes $250M break-up fee clause
Subscribe for More Information
08:21 EDTTEVA, CBSTMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
08:11 EDTCBSTCubist volatility elevated into Merck acquiring for $8.4B in cash
Subscribe for More Information
08:08 EDTCBSTMerck says about $9.5B of debt to be issued related to Cubist deal
Subscribe for More Information
07:53 EDTBPClimate for Exxon E&P acquisition improved by falling prices, WSJ says
Subscribe for More Information
07:29 EDTJAZZUBS to hold investor trip
Subscribe for More Information
07:18 EDTJAZZUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.
07:13 EDTCBSTMerck to host conference call
Subscribe for More Information
07:01 EDTCBSTMerck to acquire Cubist for $102 per share in cash, or $9.5B
Subscribe for More Information
07:00 EDTCBSTMerck to acquire Cubist for $102 per share in cash
Subscribe for More Information
06:47 EDTTEVAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
06:09 EDTBPBP to cut hundreds of U.K. jobs this week, Guardian reports
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use